Lynne S Cox

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/4936209/lynne-s-cox-publications-by-year.pdf
Version: 2024-04-28

37 papers	1,941 citations	20 h-index	44 g-index
49 ext. papers	2,146 ext. citations	6.4 avg, IF	4.95 L-index

#	Paper	IF	Citations
37	Interconnections between Inflammageing and Immunosenescence during Ageing.. *Cells*, **2022**, 11,	7.9	6
36	Crosstalk Between Senescent Bone Cells and the Bone Tissue Microenvironment Influences Bone Fragility During Chronological Age and in Diabetes.. *Frontiers in Physiology*, **2022**, 13, 812157	4.6	0
35	Linking interdisciplinary and multiscale approaches to improve healthspan new UK model for collaborative research networks in ageing biology and clinical translation. *The Lancet Healthy Longevity*, **2022**, 3, e318-e320	9.5	0
34	Intercellular Transfer of Mitochondria between Senescent Cells through Cytoskeleton-Supported Intercellular Bridges Requires mTOR and CDC42 Signalling. *Oxidative Medicine and Cellular Longevity*, **2021**, 2021, 6697861	6.7	5
33	Targeting aging cells improves survival. *Science*, **2021**, 373, 281-282	33.3	5
32	Tackling immunosenescence to improve COVID-19 outcomes and vaccine response in older adults. *The Lancet Healthy Longevity*, **2020**, 1, e55-e57	9.5	30
31	Structural basis of the anti-ageing effects of polyphenolics: mitigation of oxidative stress. *BMC Chemistry*, **2020**, 14, 50	3.7	24
30	Generation of a novel model of primary human cell senescence through Tenovin-6 mediated inhibition of sirtuins. *Biogerontology*, **2019**, 20, 303-319	4.5	1
29	Optimisation of a screening platform for determining IL-6 inflammatory signalling in the senescence-associated secretory phenotype (SASP). *Biogerontology*, **2019**, 20, 359-371	4.5	9
28	mTORC Inhibitors as Broad-Spectrum Therapeutics for Age-Related Diseases. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	37
27	The role of cellular senescence in ageing of the placenta. *Placenta*, **2017**, 52, 139-145	3.4	79
26	Small molecule modulation of splicing factor expression is associated with rescue from cellular senescence. *BMC Cell Biology*, **2017**, 18, 31		50
25	Animal and human models to understand ageing. *Maturitas*, **2016**, 93, 18-27	5	27
24	Suppression of the senescence-associated secretory phenotype (SASP) in human fibroblasts using small molecule inhibitors of p38 MAP kinase and MK2. *Biogerontology*, **2016**, 17, 305-15	4.5	72
23	Reversal of phenotypes of cellular senescence by pan-mTOR inhibition. *Aging*, **2016**, 8, 231-44	5.6	64
22	The Drosophila orthologue of progeroid human WRN exonuclease, DmWRNexo, cleaves replication substrates but is inhibited by uracil or abasic sites : analysis of DmWRNexo activity in vitro. *Age*, **2013**, 35, 793-806		5
21	Biomarkers, interventions and healthy ageing. *New Biotechnology*, **2013**, 30, 373-7	6.4	8

20	A fluorescence-based exonuclease assay to characterize DmWRNexo, orthologue of human progeroid WRN exonuclease, and its application to other nucleases. *Journal of Visualized Experiments*, **2013**, e50722	1.6	2
19	The role of DNA exonucleases in protecting genome stability and their impact on ageing. *Age*, **2012**, 34, 1317-40		24
18	Recapitulation of Werner syndrome sensitivity to camptothecin by limited knockdown of the WRN helicase/exonuclease. *Biogerontology*, **2012**, 13, 49-62	4.5	2
17	Prospects for rejuvenation of aged tissue by telomerase reactivation. *Rejuvenation Research*, **2010**, 13, 749-54	2.6	5
16	Live fast, die young: new lessons in mammalian longevity. *Rejuvenation Research*, **2009**, 12, 283-8	2.6	11
15	DmWRNexo is a 3V5Vexonuclease: phenotypic and biochemical characterization of mutants of the Drosophila orthologue of human WRN exonuclease. *Biogerontology*, **2009**, 10, 267-77	4.5	18
14	Increasing longevity through caloric restriction or rapamycin feeding in mammals: common mechanisms for common outcomes?. *Aging Cell*, **2009**, 8, 607-13	9.9	44
13	Identification and characterization of a Drosophila ortholog of WRN exonuclease that is required to maintain genome integrity. *Aging Cell*, **2008**, 7, 418-25	9.9	25
12	Hypothesis: Causes of Type 2 Diabetes in Progeroid Werner Syndrome. *Open Longevity Science*, **2008**, 2, 100-103		3
11	Modeling Werner Syndrome in Drosophila melanogaster: hyper-recombination in flies lacking WRN-like exonuclease. *Annals of the New York Academy of Sciences*, **2007**, 1119, 274-88	6.5	14
10	Correction of proliferation and drug sensitivity defects in the progeroid Werner\'s Syndrome by Holliday junction resolution. *Rejuvenation Research*, **2007**, 10, 27-40	2.6	31
9	Characterisation of the interaction between WRN, the helicase/exonuclease defective in progeroid Werner\'s syndrome, and an essential replication factor, PCNA. *Mechanisms of Ageing and Development*, **2003**, 124, 167-74	5.6	40
8	Asymmetry of DNA replication fork progression in Werner\'s syndrome. *Aging Cell*, **2002**, 1, 30-9	9.9	102
7	Homologous regions of Fen1 and p21Cip1 compete for binding to the same site on PCNA: a potential mechanism to co-ordinate DNA replication and repair. *Oncogene*, **1997**, 14, 2313-21	9.2	140
6	Multiple pathways control cell growth and transformation: overlapping and independent activities of p53 and p21Cip1/WAF1/Sdi1. *Journal of Pathology*, **1997**, 183, 134-40	9.4	85
5	Two pathways for base excision repair in mammalian cells. *Journal of Biological Chemistry*, **1996**, 271, 9573-8	5.4	393
4	A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21WAF1 and proliferating cell nuclear antigen. *Current Biology*, **1995**, 5, 275-82	6.3	258
3	Tumour suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. *BioEssays*, **1995**, 17, 501-8	4.1	279